Press Releases

Oasmia Pharmaceutical Invites Shareholders to Capital Markets Day in Stockolm on June 15th

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, is inviting shareholders and interested parties to attend a June 15 capital mark...

Oasmia convenes an extraordinary general meeting on 2 June, 2017

Uppsala, Sweden, May 10, 2017 -- Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company convenes to an extraordinary general meeting. The notice will ...

Oasmia Pharmaceutical to spin-off veterinary assets

The Company has decided to move its veterinary assets to its US subsidiary and appointed a New York based investment bank to assist in evaluating financial and strategical alternatives for those.

Increased number of shares and votes in Oasmia Pharmaceutical AB (publ)

As of May 1st 2017, the total number of shares and votes in Oasmia Pharmaceutical AB (publ) (“Oasmia”) amounts to 126,098,166 shares and votes.

Conversion of SEK 42M convertible loan in Oasmia

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) announce that the convertible loan of SEK 42,000,193.20 (series 2017:1) will be fully converted to shares.

Oasmia completes set-off private placements of new convertibles in the total amount of SEK 26 million with conversion rate of SEK 8.00

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount SEK 26,000,000 through a dir...

Oasmia successfully completes private placements of new convertibles in the total amount of SEK 42 million with conversion rate of SEK 5.95

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount SEK 42,000,193 and placed wi...

Oasmia evaluates the possibility to carry out a private placement of new convertible instruments

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company evaluates the possibility to carry out a private placement of a convertible loan of approximately ...

Oasmia intends to issue convertible to replace current convertible loan

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) intends to issue a new convertible loan to replace the convertible loan (2016:1) in the total nominal amount SEK 28 million, which m...

Interim report for the period May 2016 – January 2017

Oasmia Pharmaceutical AB (publ) Interim report for the period May 2016 – January 2017 Strategic changes within Animal Health Division